Assembly and Activation of Alternative Complement Components on Endothelial Cell-Anchored Ultra-Large Von Willebrand Factor Links Complement and Hemostasis-Thrombosis

Nancy A. Turner*, Joel Moake
Department of Bioengineering, Rice University, Houston, Texas, United States of America

Abstract

**Background:** Vascular endothelial cells (ECs) express and release protein components of the complement pathways, as well as secreting and anchoring ultra-large von Willebrand factor (ULVWF) multimers in long string-like structures that initiate platelet adhesion during hemostasis and thrombosis. The alternative complement pathway (AP) is an important non-antibody-requiring host defense system. Thrombotic microangiopathies can be associated with defective regulation of the AP (atypical hemolytic-uremic syndrome) or with inadequate cleavage by ADAMTS-13 of ULVWF multimeric strings secreted by/anchored to ECs (thrombotic thrombocytopenic purpura). Our goal was to determine if EC-anchored ULVWF strings caused the assembly and activation of AP components, thereby linking two essential defense mechanisms.

**Methodology/Principal Findings:** We quantified gene expression of these complement components in cultured human umbilical vein endothelial cells (HUVECs) by real-time PCR: C3 and C5; complement factor (CF) B, CFD, CFP, CFH and CFI of the AP; and C4 of the classical and lectin (but not alternative) complement pathways. We used fluorescent microscopy, monospecific antibodies against complement components, fluorescent secondary antibodies, and the analysis of >150 images to quantify the attachment of HUVEC-released complement proteins to ULVWF strings secreted by, and anchored to, the HUVECs (under conditions of ADAMTS-13 inhibition). We found that HUVEC-released C4 did not attach to ULVWF strings, ruling out activation of the classical and lectin pathways by the strings. In contrast, C3, FB, FD, FP and C5, FH and FI attached to ULVWF strings in quantitative patterns consistent with assembly of the AP components into active complexes. This was verified when non-functional FB blocked the formation of AP C3 convertase complexes (C3bBb) on ULVWF strings.

**Conclusions/Significance:** AP components are assembled and activated on EC-secreted/anchored ULVWF multimeric strings. Our findings provide one possible molecular mechanism for clinical linkage between different types of thrombotic and complement-mediated disorders.

Citation: Turner NA, Moake J (2013) Assembly and Activation of Alternative Complement Components on Endothelial Cell-Anchored Ultra-Large Von Willebrand Factor Links Complement and Hemostasis-Thrombosis. PLoS ONE 8(3): e59372. doi:10.1371/journal.pone.0059372

Received December 21, 2012; Accepted February 14, 2013; Published March 29, 2013

* E-mail: nturner@rice.edu

Introduction

Common clinical characteristics of the thrombotic microangiopathies, thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic-uremic syndrome (aHUS), include microvascular platelet adhesion/aggregation/occlusion, thrombocytopenia, and mechanical hemolysis. [1] TTP is often associated with a deficiency of functional ADAMTS-13 (mutations or autoantibody-inhibited), the protease responsible for regulating the size of circulating VWF multimers. There is an accumulation of ULVWF strings on endothelial cell (EC) surfaces under conditions when the ULVWF strings are secreted at increased rates combined with lower amounts of functional ADAMTS-13. [2,3] Bacterial toxins, inflammatory cytokines, phosphodiesterase inhibitors and calcium ionophore are among the agents that cause increased rates of ULVWF secretion from ECs [4–6]. aHUS is the result of excessive complement activation or, more commonly, defective regulation of proteins of the alternative complement pathway (AP). The primary effect of uncontrolled AP activity in aHUS is damage to renal endothelium, resulting in renal failure [7]. Although it has been established that AP regulation is dysfunctional in aHUS, it is unclear what initiates the AP activation. Limited activation of the AP can begin by direct hydrolysis of an intra-molecular bond in C3 to C3-H2O. Subsequent cleavage activation of C3, releasing 9 kDa fragment C3a to form C3b, and further amplification of C3b production depends on the presence of “activating surfaces” [8]. C3b (not
intact C3) attaches covalently via an exposed thioester to hydroxyl-containing amino acids (threonine, serine and tyrosine) on activating surfaces [9]. C3b then binds factor B (FB) to produce C3bBb [10,11]. FB in the C3bB complex is cleaved to active Bb by factor D (FD) to produce C3bBb, the AP C3 convertase (with t1/2 of 1–3 min) [12] that is stabilized by factor P (properdin; FP) [13–15]. The Bb in C3bBb on an activating surface cleaves fluid-phase C3 to generate additional surface-bound C3b, a process that rapidly amplifies C3b generation from C3. As the ratio of C3b to Bb increases, C3bBbC3b is formed (as the AP C3 convertase), binds C5 with high affinity, and cleaves C5 to C5b [12,16]. C5b combines with C6 and C7 to generate C5b67 complexes that insert into cell membranes. If C6 and multiple C9 molecules combine with C5b67 complexes in the cell membrane, then lytic C5b678(9)n terminal complement complexes (TCCs) are formed.

Factor H (FH) and factor I (FI) are fluid-phase negative regulatory proteins of the AP [17,18]. FH can displace Bb from C3bBb and C3bBbC3b complexes and enables F1 to cleave and inactivate C3b [19]. Heterozygous mutations of the CFH gene or autoantibody-mediated inhibition of FH are prominent causes of aHUS [20,21]. aHUS is also associated with heterozygous loss-of-function mutations of CFI, and heterozygous gain-of-function mutations in C3 or CFB [22,23].

In contrast to the AP, the classical complement pathway (CP) and lectin-activated complement pathway (LP) are initiated by C1 (complex of C1q, C1r2, C1s2) attachment to antigen-antibody aggregates or mannose/N-acetylglucosamine-binding lectin (MBL)/MBL-associated protein (MASP), respectively [24,25]. Both the CP and LP lead to cleavage and activation of C4 and C2 to generate C4b2a complexes [8,26]. Analogous to activated C3b, C2a protease in C4b2a (the classical/lectin pathway C3 convertase) cleaves C3 into active C3a and covalently to surfaces [10]. The C2a protease in C4b2a complex (TCCs) are formed.

In our experiments, the non-flowing static conditions allowed the accumulation of HUVEC-released proteins that would be washed away under flowing conditions [3,29]. Antibodies to VWF were added 2 min after the ECs were stimulated with histamine, to prevent cleavage of the secreted/anchored ULVWF strings from histamine stimulated HUVECs under non-flowing, static experimental conditions. The static conditions allow the accumulation of HUVEC-released proteins that would be washed away under flowing conditions [3,29]. Antibodies to VWF were added 2 min after the ECs were stimulated with histamine, to identify fluorescently the ULVWF strings and to prevent cleavage of the secreted/anchored ULVWF strings by HUVEC-released ADAMTS-13. Over the following 15 min complement components released from the HUVECs attached to the EC secreted/anchored ULVWF strings.

Fluorescent imaging was used to analyze the attachment of complement proteins to HUVEC-secreted and anchored ULVWF strings. The polyclonal antibodies made against human complement proteins to HUVEC-secreted and anchored ULVWF strings. The polyclonal antibodies made against human complement proteins were used in fluorescent microscopy experiments specifically identify individual complement components, as demonstrated by Western blots (Fig. 2). The serum samples applied to the gels (usually 20–25 µg/lane) contained many-fold higher amounts of protein than were secreted by the HUVECs during our experiments; nevertheless, bands for other proteins other than the specific complement factors (and corresponding cleavage fragments) were not detected by the individual mono-specific polyclonal antibodies made against the different complement components. A degradation product of C4 is detected in the C4-depleted serum and two degradation products of C5 are detected in the C5-depleted serum.

In order to analyze FD and FP in serum, the quantities of protein in gel samples were increased even further to ~100 µg/ lane. This is the maximum amount of protein per gel lane that can enter completely, and be separated effectively, in our electrophoresis system. The FD in the serum samples was still undetectable because of the low FD serum concentrations (1–2 ng/µl). In the blot detected with antibody to FP, the

**Results**

**HUVEC Gene Expression of Complement Components**

Transcripts for C3 and C5, the AP-specific complement components CFB, CFD, CFP, CFH, CFI, and the CP-specific component C4 were identified in HUVECs and quantified relative to 18S expression for the first time using real time RT-PCR (Fig. 1). TaqMan probes that recognize only cDNA transcribed from mature mRNA were used in order to exclude genomic DNA. Synthesis of CFD has never previously been detected in HUVECs by any technique. FD is required to cleave C3b-bound FB to Bb (the C3 convertase (C3bBb)) during AP activation.

The alternative pathway regulatory components CFH and CFI were the only complement genes expressed in HUVECs at levels in the range of 18S, a major synthetic product of human ECs: CFH expression was similar to 18S and CFI was ~6-fold higher. Expression levels of C5 and CFB were 10-fold and 70-fold lower, respectively; and C3, CFD and CFP were ~500 to 1200-fold lower than 18S expression levels.

Expression of the CP component C4 was 50-fold lower than 18S.

Transcripts for the VWF protease, ADAMTS13, which is also produced and released from HUVECs, [30] were ~10-fold lower than 18S transcripts. ADAMTS13 was included in this study as an additional indicator of EC transcription.

**HUVEC-released Complement Components Bind to HUVEC Secreted and Anchored ULVWF Strings**

In the presence of the EC stimulatory substance, histamine, HUVECs rapidly (within 2 min) secrete ULVWF strings from their storage vesicles [Weibel-Palade bodies (WPBs)] onto cell surfaces. We have previously demonstrated the release of anchored ULVWF strings from histamine stimulated HUVECs under non-flowing, static experimental conditions. The static conditions allow the accumulation of HUVEC-released proteins that would be washed away under flowing conditions [3,29]. In the blot detected with antibody to FP, the gels (usually 20–25 µg/lane) contained many-fold higher amounts of protein than were secreted by the HUVECs during our experiments; nevertheless, bands for other proteins other than the specific complement factors (and corresponding cleavage fragments) were not detected by the individual mono-specific polyclonal antibodies made against the different complement components. A degradation product of C4 is detected in the C4-depleted serum and two degradation products of C5 are detected in the C5-depleted serum.

In order to analyze FD and FP in serum, the quantities of protein in gel samples were increased even further to ~100 µg/lane. This is the maximum amount of protein per gel lane that can enter completely, and be separated effectively, in our electrophoresis system. The FD in the serum samples was still undetectable because of the low FD serum concentrations (1–2 ng/µl). In the blot detected with antibody to FP, the
migration of the FP standard was altered slightly by the high albumin concentration present in the FP-depleted sample in the adjacent lane. The FP in normal serum (4–6 ng/ml) was barely detectable.

The complement components in this study were not detected in HUVEC WPBs and, therefore, it is improbable that ULVWF multimers were pre-bound with complement proteins prior to their secretion. The technical details are in “Fluorescent emission ‘bleed-through’ controls” in the Material and Methods section.

In the initial fluorescent imaging experiments, the complement proteins analyzed for attachment to HUVEC-secreted and anchored ULVWF strings were synthesized and released exclusively from HUVECs and accumulated under the non-flowing experimental conditions. Neither a serum nor plasma source of the components was present in the experiments. Fluorescent images and fluorescent intensity graphs of complement components attaching along the HUVEC-secreted/anchored ULVWF strings are shown in Figs. 3, 4, 5, 6, 7, and the quantitative attachment data are summarized in Fig. 8.

AP-specific Complement Components FB, FD and FP Attach to HUVEC-secreted/anchored ULVWF Strings

Each of the AP-specific components FB, FD and FP (the positive AP regulatory protein) bound to the ULVWF strings with average fluorescent intensities per micron of ULVWF string length that were 30- to 50-fold higher than values for the classical pathway-specific component C4 (C4 data shown in Fig. 7). FB, reactive only with activated C3b not intact C3, bound most extensively to the ULVWF strings (>1600 fluorescent intensity per micron) (Fig. 3A). The measured fluorescent intensities for FP and FD (~1000 units/micron) were also high, considering the low expression levels of these components in HUVECs (as shown in Fig. 1). This demonstrates a high affinity of FD and FP for HUVEC-anchored ULVWF strings (Fig. 3B–C).

AP-specific Regulatory Components FH and FI Attach to HUVEC-secreted/anchored ULVWF Strings

Fluorescent intensities measured for the AP-specific negative regulatory components FH and FI along the ULVWF strings were similar to each other (Fig. 4A–B, ~2400 units/micron), averaging ~30 to 40% lower than the fluorescence measured for the most extensively bound complement components, C3 and C5, as discussed below. FH displaces FB or Bb bound to C3b, thereby preventing further AP activation. FH also acts as a cofactor for the FI proteolysis and inactivation of C3b.

Complement Components C3 and C5 Attach to HUVEC-secreted and Anchored ULVWF Strings

HUVEC-released C3 (in the form of C3b) was the complement component that bound most extensively to the secreted/anchored ULVWF strings, with average intensities of ~4000 fluorescent intensity units per micron of ULVWF string length (Fig. 5A). HUVECs synthesize low levels of C3, as demonstrated by C3 mRNA levels in Figure 1; however, the extensive attachment of C3 indicates a high level of affinity of C3 for the HUVEC-anchored strings.

C5 released from HUVECs was the second most abundant complement component detected along HUVEC-anchored ULVWF strings (>3000 fluorescent intensity units per micron) (Fig. 5B).

The binding of C5 suggests that C5 convertases (C3bBbC3b) have formed on the ULVWF strings because C5 binds preferentially to C3b molecules within or adjacent to C3bBbC3b complexes [16]. This interpretation was confirmed by the demonstration that C3 and C5 often attached to the same positions on HUVEC-secreted/anchored ULVWF strings (Fig. 6).

In these experiments, C3 was detected using a combination of two mouse monoclonal antibodies. One of the monoclonal antibodies was reactive only with C3b.

Figure 1. Gene expression of complement components in HUVECs. HUVECs were maintained for 24 hours in serum-free medium prior to RNA extraction. Total RNA was isolated, reverse transcribed, and the cDNA was analyzed by real-time PCR using TaqMan probes with GAPDH as the reference gene. The graph shows fold differences (log scale) of complement component expression in unstimulated HUVECs relative to VWF expression (marked by asterisk). The line at 1 is the boundary between increased and decreased expression. Data shown are means plus SD, N=4. Values for ADAMTS13 (A13) are shown for comparison.
doi:10.1371/journal.pone.0059372.g001
Classical and Lectin Pathway Complement Component C4 Does Not Attach to HUVEC-secreted/anchored ULVWF Strings

In contrast to C3 and C5, and the AP-specific components, there was almost no binding of classical component C4 to ULVWF strings. The average C4 fluorescent intensity measured along the strings was 100-fold less per micron than the intensities measured for C3 or C5 (Fig. 7).

Quantitative Summary

The quantitative data of exclusively HUVEC-released complement component binding to EC-secreted/anchored ULVWF strings is summarized in Fig. 8. The fluorescent intensity at 594 nm (red), used for detection of the complement proteins attached to HUVEC-anchored ULVWF strings, was not a result of fluorescent “bleed through” from the 488-nm channel (green) used for VWF detection. The experimental details that confirm this conclusion are in the Materials and Methods section.

Complement Components do not Bind to Surfaces of Unstimulated HUVECs

Neither C3 nor C5 exclusively released from the HUVECs, or added in heated serum was detected on unstimulated HUVEC surfaces devoid of ULVWF strings. The absence of C3 and C5 on HUVEC surfaces, along with the absence of anchored ULVWF strings, indicates that C3 and C5 were only bound to HUVEC-secreted/anchored ULVWF strings in our experiments (Fig. 9).

Non-functional FB Reduces the Amounts of AP Components on EC-secreted/anchored ULVWF Strings: Functional Evidence for C3bBbC3b (C3 convertase) and C3bBbC3b (C5 Convertase) Assembly

The concentrations of complement proteins in normal human serum are many-fold higher than the accumulated amounts released by the HUVECs over the 15 min time period of the previous experiments (summarized in Fig. 8). In the experiments described in this section, heated serum (diluted to 25% in PBS) was added to HUVECs during histamine stimulation. Binding intensities per micron along EC-anchored ULVWF strings was compared for C3, C5 and FB with the previous experiments using exclusively HUVEC-released complement proteins. Heating to 56°C was necessary in order to prevent heat-labile serum ADAMTS-13 from cleaving the EC-anchored ULVWF strings prior to the addition of antibody to VWF (which also blocks ADAMTS-13-mediated VWF cleavage). The functions of C3 and C5 are unaffected by 56°C heat. In contrast, heating to 56°C completely inhibits the proteolytic function of FB [31].

The non-functional, structurally altered, heated form of FB exhibited an increased capacity for binding to HUVEC-anchored ULVWF strings. The binding intensities of non-functional FB per micron of ULVWF string in heated serum experiments were 2-fold higher than the intensities of functional FB released exclusively from HUVECs (Fig. 10). In contrast, less than half as much functional C3 from heated serum attached to ULVWF strings compared to the amounts of functional C3 attached exclusively from HUVECs (Fig. 10). These results suggest that reduced amounts of activated C3 (C3b) were generated, in the absence of functional FB, even though increased amounts of fluid-phase C3 were available in the heated serum. We conclude that heated, enzymatically-inactive serum FB bound competitively to C3b on the ULVWF strings and formed inactive C3b-FB complexes instead of active C3 convertases (C3bBb). Inactive C3b-FB complexes are incapable of the proteolytic cleavage of C3 to activated C3b that is required to attach C3b to certain surfaces (in these experiments, to HUVEC-anchored ULVWF strings).

The binding of C5 to ULVWF strings also did not increase with the addition of higher quantities of functional C5 in heated serum (Fig. 10). This is compatible with a reduced number of ULVWF string-bound C3b molecules restricting binding sites for C5 on C3b molecules adjacent to, or in, C3bBbC3b (C5 convertase) complexes [12,16]. The large increase in heat-inactivated FB binding to the EC-anchored ULVWF strings may further restrict C5 binding to the ULVWF strings by sterically hindering the access of C5 to binding sites on C3b.

Discussion

In earlier reports, HUVEC transcripts of CFH [32,33] and C5 [34] were easily identified; however, gene expression of other complement proteins was less convincing [33,35,36]. CFD expression in HUVECs had not previously been investigated. In our study, transcripts for complement components C3, C4A, C5, CFB, CFD, CFH, CFI and CFP were verified and quantified relative to VWF expression in unstimulated HUVECs using real-time PCR and TaqMan expression assays.

AP negative regulatory components CFH and CFI were the only complement genes expressed in HUVECs at levels comparable to VWF. These results indicate that EC synthesis of FH and FI are important for EC self-protection.

Excessive secretion/anchorage of endothelial cell-ULVWF strings occurs in response to endothelial cell stimulation by many agents, including histamine, shiga toxins, and inflammatory cytokines [4–6,28]. Under our experimental conditions, [3] ADAMTS-13 cleavage of cell-bound ULVWF strings is diminished or delayed, allowing the AP components to attach to, and initiate C3b amplification, by the activating surfaces of the strings. In the majority of the complement/ULVWF string binding experiments in this study (Figures 3, 4, 5, 6, 7, 8), ADAMTS-13 was released from the HUVECs (along with complement components) during the 2 min histamine stimulation and the 10 min time period when the cells were incubated with the anti-VWF antibody and fluorescent secondary antibody combination. The cleavage function of the ADAMTS-13 during the 2 min stimulation was suppressed by the use of a relatively large volume of fluid surrounding the cells (1 ml per 4.8 cm² of surface area) that reduced the affective concentration of released ADAMTS-13 near the surface of the HUVECs as the ULVWF strings were secreted and anchored. After the addition of the anti-VWF antibody, ADAMTS-13 was no longer capable of cleaving the (anti-VWF-coated) ULVWF strings [3,29]. We make the analogy between
restricted of ADAMTS-13 activity (allowing some ULVWF strings to remain uncleaved for our studies) and TTP or other thrombotic microangiopathies with ADAMTS-13 activity that may be inadequate for the rate of EC-secretion/anchorage of ULVWF strings (augmented by cytokines in infection or inflammation).

Stimulation of HUVECs with histamine may result in the release of other EC proteins or altered EC surface protein exposure, in addition to WPB secretion of ULVWF strings. This could account for the background binding (or cell surface binding) of some complement proteins. Our studies were restricted to the detection and measurement of complement proteins that were bound to the HUVEC-secreted/anchored ULVWF strings. Background subtraction of an equal number of data points, within the same images and in parallel locations, makes it unlikely that the measured intensities of the complement components on the ULVWF strings were the result of random fluorescent binding.

Following the rapid secretion of ULVWF from WPBs, ULVWF multimeric strings remain anchored to EC surfaces until smaller VWF multimers are released into the plasma by ADAMTS-13 cleavage of the EC-secreted/anchored ULWVF. Without an anchor point, the plasma-type small VWF multimers adopt a less accessible globular conformation. Although we did not investigate complement component interaction with plasma-type VWF multimers, it is possible that the C3b recognition sites present on EC-anchored ULVWF strings are not accessible (or less accessible) on the globular conformation of plasma-type VWF.

In our studies, brief stimulation times and addition of VWF antibodies (that block ADAMTS-13-mediated cleavage) combined to restricted the cleavage of EC-secreted/anchored ULVWF strings by HUVEC-derived ADAMTS-13. We previously demonstrated that the addition of antibodies to VWF does not prevent HUVEC-released ADAMTS-13 from attachment to EC-secreted/anchored ULVWF strings [3]. The current experiments demonstrate interactions between ULVWF strings and complement components released from stimulated HUVECs. With the exception of C4 (a component essential for CP and LP activation), each of the other AP complement components studied (C3, C5, and AP-specific proteins FB, FD, FH, FI, and FP) attached to the HUVEC-anchored ULVWF strings.

Small amounts of C3 are released from many cell types (including HUVECs) and can be hydrated to an activated form (C3-H2O) that initiates the conversion of C3 to C3b. Cleavage of C3 releases the small C3a fragment and exposes a thioester in C3b that covalently attaches to “activating surfaces” [10]. As shown by our experiments, these include EG-anchored ULVWF strings. Binding affinities of FH for C3b decrease as a result of the structural changes that occur in C3b as it binds to an activating surface [11,37]. The conformational changes in C3b after its attachment to cell-anchored ULVWF strings may limit the capacity of FH and FI to bind and inactivate C3b. This would favor the assembly of C3 convertase (C3bBb) by FB, FD, and FP, and would allow amplification of C3 conversion to C3b and promote additional C3b attachment to the strings.

The assembly and activation of HUVEC-released AP components on EC-bound ULVWF strings would be associated with: HUVEC-released functional FB and C3b binding to each other on the ULVWF strings, followed by FB cleavage to Bb by HUVEC-released FD; the formation of string-bound C3 convertase (C3bBb) complexes; and amplification of C3b generation from C3. In the presence of heated serum, which contains high concentrations of functional C3 and non-functional FB, there was a decrease in C3b binding to HUVEC-anchored ULVWF strings compared to experiments when functional C3 and FB were released exclusively from HUVECs. We conclude that a considerable quantity of C3b binding to the strings, using HUVECs alone, was the result of string-bound C3bBb (C3 convertase) assembly and amplification of C3b generation from HUVEC-released C3. In the presence of non-functioning FB in the heated serum, a poorly functioning C3 convertase assembled on the ULVWF strings.

Detection on the EC-anchored ULVWF strings of HUVEC-released C3, FB and C5 implies that both the alternative pathway C3 convertase and the C5 convertase assemble on EC-secreted/anchored ULVWF strings. The attachment of HUVEC-released C3 (after cleavage to C3b) on ULVWF strings was ~30% greater than the attachment of HUVEC-released C5 to the strings. As the number of C3b molecules attached to an activating surface increases to form C3bBbC3b complexes, then C5 binds with higher affinity to the accumulating C3b molecules [12,16]. These data are compatible with the formation of some C3bBbC3b (C5 convertase) complexes capable of binding C5 on the ULVWF strings. This was demonstrated conclusively in images of C3 and C5 attached to the same points along HUVEC-secreted/anchored ULVWF strings.

The assembled C3 convertase (C3bBb) and C5 convertase (C3bBbC3b) complexes on EC-anchored ULVWF strings may generate TCCs [C5b6789]+. The C5 convertase cleaves C5 to C5b en route to the formation of C5b678 complexes, which can be inserted into cell membranes to associate with multiple C9 molecules. HUVEC membranes have CD46, thrombomodulin and DAF (decay-accelerating factor; CD55) to prevent surface C3 and C5 convertase assembly or persistence [18]. Endothelial cells also have cell surface CD59 and secreted vitronectin (S-protein) and clusterin to protect against TCC formation [18,38]. We could not detect surface TCCs or soluble SC5b-9 complexes in our cell experiments, and we did not observe HUVEC lysis. If terminal complexes were generated during the short duration of our experiments, the amounts may have been too low to be detected by the polyclonal and monoclonal anti-SC5b-9 antibodies used in our assays. EC regulatory proteins may have protected HUVECs...
Figure 4. AP-specific negative regulatory components FH and FI attach to ULVWF strings secreted by, and anchored to, stimulated HUVECs. HUVECs were stimulated and stained as in the legend for Fig. 3, except that antibody to human FH was used in (A) and antibody to human FI in (B) to identify complement component attachment to the ULVWF strings. In (A) panel 6, only the locations of the background intensities are identified by the dotted line. In (B) panel 6, the upper dotted line shows the location of the FI intensity measurements and the lower dotted line identifies the locations of background intensity measurements. The white arrows in (3) indicate FH (A) and FI (B) attachment to the strings. Images were selected from 12 (FH) and 4 (FI) independent experiments.

doi:10.1371/journal.pone.0059372.g004
against lysis by any small quantities of TCCs were generated during our experiments.

Possible targets of any TCCs generated by activation of the alternative complement pathway on endothelial cell secreted/anchored ULVWF strings include microbes and injured or defective tissue (including endothelial) cells. In addition to histamine, calcium ionophore and phosphodiesterase inhibitors, ULVWF strings are secreted from endothelial cells that have been stimulated by cytokines (TNFα, IL-6, IL-8) associated with infection and inflammation [6].

We have demonstrated the interaction and probable assembly/activation of alternative complement components on endothelial cell-secreted/anchored ULVWF strings. The findings may have pathophysiological and potential therapeutic importance in thrombotic and complement-mediated inflammatory disorders, and provide one possible molecular mechanism for recent observations suggesting clinical links between different types of thrombotic microangiopathies. [39–42] Possible new therapy, in addition to a monoclonal antibody to C5 currently available, [43] includes blockade of the AP C3 convertase using heat-inactivated FB that is described for the first time in our report.

Materials and Methods

Ethics Statement

All work on human VWF, human endothelial cells including experiments in this study have been specifically approved by the Rice Institutional Review Board (IRB). Human tissues and blood samples were collected under a protocol approved by the Rice IRB. Donors provided their written informed consent to participate in the study. Protocol Name: Processing of Large von Willebrand Factor (VWF) Multimers: VWF Cleavage, Thrombosis and Platelet Aggregation, Protocol Number: 11-183E. The Rice
Figure 7. C4, a component of the classical and lectin pathways, does not attach to ULVWF strings secreted by, and anchored to, stimulated HUVECs. HUVECs were stimulated and stained as in the legend for Fig. 3, except the antibody to human C4 was used to identify complement component attachment to the ULVWF strings. In panel 6, the upper dotted line shows the location of the C4 intensity measurements and the lower dotted line identifies the locations of background intensity measurements. Images were selected from 4 experiments.
doi:10.1371/journal.pone.0059372.g007

Figure 8. Quantification of HUVEC-released complement components attached to HUVEC-secreted/anchored ULVWF strings. Intensities of each HUVEC-released complement proteins were measured along histamine-stimulated HUVEC-secreted/anchored ULVWF strings, as described in the legend for Fig. 3. Shown are the complement component fluorescent intensities per micron of ULVWF string length after background subtraction. Values are means plus SD; N = 7–12 strings for each complement component from 4 to 12 experiments and were compiled from 130 fluorescent images. Some data were collected from images within the same experiment at a different location on the coverslip.
doi:10.1371/journal.pone.0059372.g008
IRB reviews protocols annually and has approved of this consent procedure and study through 5/13/2013.

Complement Components and Antibodies

Goat polyclonal antibodies to individual human complement components, purified human complement proteins, and human sera depleted of each specific complement factor were obtained from Complement Technology (Tyler, TX). Monospecific reactivity of each complement antibody was verified by Western blotting using sets of purified complement proteins, normal sera and component-specific depleted sera. Each polyclonal complement antibody was reactive against the intact component protein and the corresponding cleavage fragments. Complement C3 was also identified using a combination of mouse anti-human C3b (clone 755) and anti-human C3 (clone 10A1) monoclonal antibodies (Pierce/Thermo Scientific) in the fluorescent microscope experiments. The average serum concentrations of complement proteins in this study are: C3 1300 mg/ml; C4 400 mg/ml; C5 75 mg/ml; FB 200 mg/ml; FD 2 mg/ml; FH 500 mg/ml; FI 35 mg/ml; and FP 5 mg/ml.

Western Immunoblots

Denatured, non-reduced samples in sodium dodecyl sulfate (SDS) were electrophoresed into 4–15% polyacrylamide gels (BioRad), stained with Bio-Safe Coomassie G-250 and transferred to PVDF membranes. Membranes were overlaid separately with monospecific polyclonal goat antibodies to each complement component, followed by secondary rabbit anti-goat IgG-HRP plus StrepTactin-HRP conjugate and chemiluminescent reagents (WesternC, BioRad), before digital imaging (ChemiDoc XRS, BioRad). Each blot in Figure 2A contains lanes with: 50 ng of a purified complement protein (Std), normal serum (NS) containing 50 ng of the specific complement component, an equal volume of specific complement component-depleted sera and StrepTactin-labeled protein standards. Goat antibody to FD was pre-adsorbed with FD-depleted sera using a 1:4 ratio.

Human Umbilical Vein Endothelial Cells (HUVECs)

Primary HUVECs were isolated from umbilical veins as previously described [5]. Cells were seeded in flasks or on glass coverslips for microscopy experiments and grown in Endothelial Basal Medium (EBM, Lonza, Hopkinton, MA), supplemented with 3% penicillin-streptomycin (P/S), 0.2 mM L-glutamine and Low Serum Growth Supplement (Invitrogen). HUVECs used for RNA isolation were incubated for 24 hours in serum-free EBM plus insulin-transferrin-selenium (ITS, Invitrogen). HUVEC RNA isolated to calculate efficiencies for CFD and CFP were incubated for 24 hours ±100 μM histamine followed by 24 hours in serum-free EBM plus ITS.
Fibroblasts

Human adult dermal fibroblasts were purchased from American Type Culture Collection (Manassas, VA) and maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) plus 3% P/S, glutamine and 10% fetal bovine serum (Atlanta Biological). Prior to RNA extraction, fibroblasts were incubated for 24 hours ±100 ng/ml lipopolysaccharide (LPS, Sigma) followed by 24 hours in serum-free DMEM plus ITS ±100 ng/ml LPS.

Relative Quantitative Gene Expression

HUVEC and fibroblast RNA was isolated using TRIzol (Invitrogen), chloroform extraction and isopropanol precipitation. RNA integrity was verified by 260/280 optical density ratios and 1%-agarose-formaldehyde electrophoresis, and was reverse transcribed using SuperScript III Superscript (Invitrogen). Samples (100 ng cDNA) were amplified in quadruplicate by real-time polymerase chain reaction (PCR) under conditions: 95°C for 10 sec, 40 cycles of (10 sec at 95°C, 10 sec at 55°C, 30 sec at 72°C), and 95°C for 10 sec followed by melting curves from 65° to 95°C (CFX96, BioRad). Amplified products were detected using TaqMan Gene Expression Assays (with 6-carboxyfluorescein-labeled probes that span target exon junctions) and Fast Advanced TaqMan Gene Expression Assays (with 6-carboxyfluorescein-95 uC3 was detected within 40 cycles with 10 ng cDNA or lower. To alleviate this problem, RNA from cultured human dermal fibroblasts with/without exposure to LPS was isolated and the cDNA was used to calculate the probe efficiency for C3. Fibroblast expression of C3 was 39-fold higher than in HUVECs. The addition of 100 ng/ml LPS to fibroblast cultures increased C3 levels 19-fold further, resulting in sufficient mRNA to calculate C3 probe efficiencies. Although HUVEC mRNA levels for CFD and CFP were comparably as low as C3, the transcripts for CFD and CFP increased 2- and 3-fold, respectively, in HUVECs exposed to histamine. The RNA isolated from the histamine stimulated HUVECs was used to calculate efficiencies for the CFD and CFP probes. The fold-changes in HUVEC mRNA gene expression with exposure to histamine (treated) and without histamine (control) were calculated with equation (2) using GAPDH as the reference gene. The standard deviation in gene expression assays (S) was determined by the equation:

\[ S = \sqrt{s_1^2 + s_2^2} \]

where \( S_1 \) and \( S_2 \) are the standard deviations of quadruplicate Ct measurements for the reference and target genes.

Fluorescent Microscopy Studies

Fluorescent images were acquired using IP Lab software version 3.9.4r4 (Scanalytics, Inc., Fairfax, VA) on a Nikon Diaphot TE300 microscope equipped with a CFI Plan Fluor 60× oil N.A. 1.4 objective plus 10X projection lens (Nikon, Garden City, NY), SensiCamQE CCD camera (Cooke Corp., Romulus, MI), motorized stage and dual filter wheels (Prior) with single band excitation and emission filters for FITC/TRITC/CY5/DAPI (Chroma, Rockingham, VT). VWF and complement proteins were imaged using the following primary antibody and fluorescent secondary antibody pairs: polyclonal rabbit anti-human VWF (Ramco Laboratories, Sugarland TX) plus Alexa Fluor 488 (green) chicken anti-rabbit IgG (Invitrogen); goat polyclonal antibodies to individual human complement components plus Alexa Fluor 594 (red) donkey anti-goat IgG (Invitrogen). Complement C3 was also imaged using a combination of mouse anti-human C3b (clone 755) and anti-human C3 (clone 10A41) monoclonal antibodies (Pierce/Thermo Scientific) plus Alexa Fluor 647 goat anti-mouse F(ab')2.
IgG (Invitrogen). Cell nuclei (blue) were detected with 1 nM 4,6 diamidino-2-phenylindole (DAPI).

**Normal Serum**

Sera from normal consenting donors collected under a protocol approved by the Rice University Institutional Review Board were pooled and stored at ~80°C until use. Before cell experiments, pooled serum was heated to 56°C for 15 min (heated serum) and diluted to 25% in PBS.

**Interaction of HUVEC-secreted/anchored ULVWF Strings with Complement Components Released from HUVECs or Present in Heated Normal Serum**

HUVECs seeded on 4.8 cm² glass coverslips were washed with PBS and stimulated with 100 μM histamine in 1 ml of PBS for 2 min followed directly by immunostaining; or with 100 μM histamine in 25% heated serum/PBS for 5 min followed by 4 PBS washes before staining. The cytokines TNFα, IL-8 and IL-6 (+ receptor), shiga toxins-1 and -2 and histamine stimulate ECs to secrete surface-anchored ULVWF strings [5,6]. Histamine was used in this study to stimulate the HUVECs. Followed histamine stimulation under both conditions, cells were immunostained with rabbit anti-VWF plus anti-rabbit IgG-488 for 15 min and fixed for 10 min with 1% p-formaldehyde. The fixed HUVECs were then stained separately with goat anti-human complement component antibodies plus anti-goat IgG-594 for 10 min. Cell nuclei were detected with DAPI. For unstimulated control experiments, HUVECs on coverslips were treated and stained as the heated serum-incubated cells except the histamine was omitted.

**Evaluation of HUVEC-secreted/anchored ULVWF Strings and Complement Component Interaction**

HUVEC-anchored ULVWF strings detected with rabbit anti-VWF plus fluorescent anti-rabbit IgG-488 were electronically traced in 488-nm (green)-captured images at 600X magnification, and the emitted fluorescent intensity was measured and integrated along the line. The x- and y-coordinates of the traced ULVWF line were transferred to the corresponding 594-nm (red)-captured images obtained using specific polyclonal goat antibodies against single complement components plus fluorescent anti-goat IgG-594 for 10 min. Cell nuclei were detected with DAPI. For unstimulated control experiments, HUVECs on coverslips were treated and stained as the heated serum-incubated cells except the histamine was omitted.

**Fluorescent Emission ‘Bleed-through’ Controls**

We did not detect any of the complement components in HUVEC Weibel-Palade bodies. For C3, this is in agreement with Misumi, et al., who previously showed that precursor C3 protein, after furin cleavage, is not sorted to a storage vesicle [43]. Unstimulated HUVECs were fixed and treated with Triton-X to allow intracellular staining, and then immunostained with anti-VWF antibody plus 488-secondary antibody. VWF staining was followed by addition of each complement antibody plus 594-secondary antibody in separate experiments. Because WPBs contain a high concentration of VWF and are devoid of complement components, these organelles were used to demonstrate the separation of fluorescent signals obtained at 488 and 594 nm in our microscope system. The fluorescent intensity at 594 nm (red), used for detection of the complement proteins attached to HUVEC-anchored ULVWF strings, was not a result of fluorescent “bleed through” from the 488-nm channel (green) used for VWF detection. This was demonstrated by the following experiments. Non-stimulated HUVECs were treated with 0.02% Triton-X to allow internal WPB staining followed by: (1) staining with rabbit antibodies to VWF plus secondary anti-rabbit IgG-488; and (2) goat antibodies to AP components plus secondary anti-goat IgG-594. Intensities were measured across WPBs located by high levels (up to 2500 fluorescence intensity units) of VWF-positive fluorescence in 488-nm images (green), and in identical locations in 594-nm (red) images. The levels measured in the 594-nm channel were <100 fluorescence intensity units per micron, confirming that there was little or no fluorescent “bleed through” during image acquisition for the experiments with ULVWF strings (green) and the different complement components (red) (Fig. 11).

**Author Contributions**

Conceived and designed the experiments: NAT JM. Performed the experiments: NAT. Analyzed the data: NAT. Contributed reagents/materials/analysis tools: NAT. Wrote the paper: NAT JM.

**References**

1. Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347: 589-600.
2. Turner N, Nolasco L, Moake J (2012) Generation and Breakdown of Soluble Ultra-large von Willebrand Factor Multimers. Semin Thromb Hemost 38: 38–46.
3. Turner NA, Nolasco L, Ruggeri ZM, Moake JL (2009) Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood 114: 5102-5111.
4. Huang J, Moto DG, Bundle DR, Sadler JE (2010) Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombois microangiopathy in ADAMTS13-deficient mice. Blood 116: 3633–3639.
5. Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TG et al. (2005) Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 106: 4199-4209.
6. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF (2004) Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultra-large von Willebrand factor multimers under flow. Blood 104: 100-106.
7. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C et al. (2011) Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 365: 8-26.
8. Law SK, Levine RP (1977) Interaction between the third complement protein and cell surface macromolecules. Proc Nad Acad Sci U S A 74: 2701–2705.
9. Pangburn MK, Ferreira VP, Cortes C (2008) Discrimination between host and pathogen by the complement system. Vaccine 26 Suppl 8: 115-21.
10. Law SK, Dodds AW (1997) The internal theocon and the covalent binding properties of the complement proteins C3 and C4. Protein Science 6: 263-274.
11. Schreiber RD, Pangburn MK, Lesavre PH, Müller-Eberhard HJ (1978) Inhibition of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. PNAS 75: 3948-3952.
12. Rawal N, Pangburn M (2001) Formation of high-affinity C5 convertases of the alternative pathway of complement. J Immunol 166: 2635-2642.
13. Fearon DT, Austen KF, Rudolph S (1973) Formation of a hemodynamically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med 138: 1303–1313.
Alternative Complement Components and ULVWF

14. Pilliner L, Blum L, Lepow IH, Ross OA, Todd EW et al. (1954) The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120: 279–283.

15. Weiler JM, Daha MR, Austen KF, Fearon DT (1976) Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A 73: 3268–3272.

16. Kinoshita T, Takata Y, Kozono H, Takekita J, Hong KS et al. (1988) C3 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme. The Journal of Immunology 141: 3895.

17. Abarrategui-Garrido C, Melgosa M, Pena-Carrion A, de Jorge EG, de Cordoba SR et al. (2006) Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Am J Kidney Dis 52: 171–180.

18. Morgan BP, Harris CL (1999) Complement regulatory proteins. (Academic Press, London), p. 59–69, p. 121–125.

19. Pangburn MK (1986) Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases. J Immunol 136: 2216–2221.

20. Loirat C, Fremaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet Journal of Rare Diseases 6: 60.

21. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJH (2010) Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Human Mutation 31: E1445–E1460.

22. Fremaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J et al. (2008) Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112: 4948–4952.

23. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA et al. (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 104: 241–245.

24. Matoush H, Fujita T (1992) Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med 176: 1497–1502.

25. Ziccardi RJ (1981) Activation of the early components of the classical complement pathway under physiologic conditions. J Immunol 126: 1769–1773.

26. Nagasawa S, Stroud RM (1977) Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b. Proc Natl Acad Sci U S A 74: 2996–3001.

27. Dong JF, Moake JL, Nolasco L, Bernardo A, Arcegaux W et al. (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100: 4033–4039.

28. Michaux G, Abbott KB, Collinson LM, Haberichter SL, Norman KE et al. (2006) The physiological function of von Willebrand factor's cleavage factor depends on its tubular storage in endothelial Weibel-Palade bodies. Dev Cell 10: 223–232.

29. Turner N, Nolasco L, Dong JF, Moake J (2009) ADAMTS-13 cleaves long von Willebrand factor multimers anchored to endothelial cells in the absence of flow, platelets or conformation-altering chemicals. J Thromb Haemost 7: 229–232.

30. Turner N, Nolasco L, Tao Z, Dong JF, Moake J (2006) Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 4: 1396–1404.

31. Chapitis J, Lepeszies IH (1979) Physical Characterization of the Effect of Heat on Factor B Of the Properdin System. J Immunol 123: 1768.

32. Broomans RA, van der Ark AA, Buurman WA, van Es LA, Daha MR (1990) Differential regulation of complement factor H and C3 production in human umbilical vein endothelial cells by IFN-gamma and IL-1. J Immunol 144: 3835–3840.

33. Ripoche J, Mitchell JA, Erdei A, Madin C, Moffatt B et al. (1988) Interferon gamma induces synthesis of complement alternative pathway proteins by human endothelial cells in culture. J Exp Med 168: 1917–1922.

34. Langegger H, Berege KE, Macor P, Fischetti F, Tedesco F et al. (2001) Detection of mRNA for the terminal complement components C5, C6, C7 and C9 in human umbilical vein endothelial cells in vitro. APMIS 109: 73–78.

35. Bongrazio M, Fries AR, Zakrzewicz A (2003) The endothelium as a physiological source of properdin: role of wall shear stress. Mol Immunol 39: 669–675.

36. Klegeris A, Bissonnette CJ, Dorociacz-Kiss K, McGeer PL (2000) Expression of complement messenger RNAs by human endothelial cells. Brain Res 871: 1–6.

37. Meri S, Pangburn MK (1990) Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a siatic acid/polyanion binding site on factor H. J Exp Med 176: 1497–1502.

38. Gandhi J, Cashman SM, Kumar-Singh R (2011) Soluble C5b9 expressed from an adenovirus in vivo is a potent inhibitor of complement deposition on murine liver vascular endothelium. PLoS One 6: e21621.

39. Noris M, Mesca F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8: 622–633.

40. Patchan D, Korsten P, Behala A, Vaiko R, Heeg M et al. (2011) Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report. J Med Case Rep 5: 598.

41. Reti M, Farkas P, Guika D, Razos K, Schlammadinger A et al. (2012) Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 10: 791–798.

42. Feng S, Kroil MH, Nolasco L, Moake J, Afshar-Kharghan V (2013) Complement activation in thrombotic microangiopathies. Br J Haematol 160(3): 404–406.

43. Chapin J, Weikler B, Magro C, Laurence J (2012) Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 157(6): 772–774.

44. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e43.

45. Misumi Y, Oda K, Fujiwara T, Takami N, Tashiro K et al. (1991) Functional expression of furin demonstrating its intracellular localization and endoprotease activity for processing of proalbumin and complement pro-C3. J Biol Chem 266: 16054–16059.